Meitav Investment House Ltd. Grows Holdings in Cellebrite DI Ltd. $CLBT

Meitav Investment House Ltd. raised its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 34.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,954,846 shares of the company’s stock after buying an additional 500,000 shares during the period. Meitav Investment House Ltd.’s holdings in Cellebrite DI were worth $26,938,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cooper Creek Partners Management LLC purchased a new stake in shares of Cellebrite DI during the third quarter worth about $55,999,000. Granahan Investment Management LLC grew its stake in Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after purchasing an additional 2,411,726 shares in the last quarter. Capital International Investors acquired a new stake in Cellebrite DI during the 4th quarter valued at approximately $41,073,000. Invesco Ltd. increased its holdings in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the last quarter. Finally, Pertento Partners LLP increased its holdings in Cellebrite DI by 57.8% during the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Trading Up 1.5%

NASDAQ CLBT traded up $0.25 on Tuesday, hitting $16.86. 445,582 shares of the stock traded hands, compared to its average volume of 1,996,110. The stock has a 50-day moving average of $13.48 and a 200 day moving average of $14.57. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98. The company has a market capitalization of $4.21 billion, a P/E ratio of 60.10, a price-to-earnings-growth ratio of 1.94 and a beta of 1.17.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CLBT. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. DA Davidson started coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target for the company. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Insider Buying and Selling

In related news, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the sale, the chief executive officer directly owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 116,457 shares of company stock valued at $1,795,835 over the last quarter. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.